DGAP-News: Neovacs S.A. / Key word(s): Conference
Neovacs to Present at Bio International Convention 2016
30.05.2016 / 08:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
Neovacs to Present at Bio International Convention 2016
Paris and Boston, May 30th, 2016 - Neovacs (Alternext Paris: ALNEV) a
leader in active immunotherapy for the treatment of autoimmune diseases,
today announced its participation at the Bio International Convention, one
of the major international conventions focused on the biotechnology
industry, being held June 6 to 9, 2016, in San Francisco, CA.
The Convention brings together established and emerging leaders in the
global biotechnology and pharmaceutical industry. In a presentation on
Monday, June 6, at 2:30pm PDT (UTC-7 pm), Miguel Sieler, CEO of Neovacs
will discuss the Company's proprietary Kinoid technology, providing updates
about Neovacs' pipeline and strategic development programs for 2016/2017.
He will also be accompanied by two members of the scientific management
team: Dr Thérèse Croughs, Chief Medical officer, and Geraldine Vogel,
Scientific Director of Neovacs.
"We are pleased to participate in this event, which is an excellent
opportunity to meet other major companies from our industry," commented
Miguel Sieler, CEO of Neovacs. "This year, our participation will be more
significant, as we obtained IND approval from the Food and Drug
Administration in the United States for our Phase IIb study of IFNα-Kinoid
in the treatment of Lupus, which allows us to broaden our visibility and
increase the interest in our technology platform."
Meet Neovacs' team at booth #413, South & North Hall
of the Moscone Center in San Francisco, California, USA
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused
on an active immunotherapy technology platform (Kinoids) with applications
in autoimmune and/or inflammatory diseases. On the basis of the company's
proprietary technology for inducing a polyclonal immune response (covered
by five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy
being developed for the indication of lupus and dermatomyositis. Neovacs is
also conducting preclinical development works on other therapeutic vaccines
in the fields of auto-immune diseases, oncology and allergies. The goal of
the Kinoid approach is to enable patients to have access to safe treatments
with efficacy that is sustained in these life-long diseases. www.neovacs.fr
Contacts
NEOVACS - Corporate Communication & Investor Relations
Charlène Masson
+33 (0)1 53 10 93 14
cmasson@neovacs.com
Investor Relations / Financial Communications Germany - MC Services
Raimund Gabriel
+49-89-21-02-28-30
raimund.gabriel@mc-services.eu
Press / U.S. Inquiries - The Ruth Group
Lee Roth / Joseph Green
+1-646-536-7012 / 7013
lroth@theruthgroup.com / jgreen@theruthgroup.com
---------------------------------------------------------------------------
30.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Neovacs S.A.
3-5, Impasse Reille
75014 Paris
France
Phone: +33 (0)1 53 10 93 00
Fax: +33 (0)1 53 10 93 03
E-mail: www.neovacs.fr
Internet: info@neovacs.fr
ISIN: FR0004032746
WKN: A1CVKR
Listed: Regulated Unofficial Market in Stuttgart; Open Market in
Frankfurt
End of News DGAP News Service
---------------------------------------------------------------------------
467283 30.05.2016
DGAP-News: Neovacs to Present at Bio International Convention 2016
| Source: EQS Group AG